Merck's tulisokibart meets Phase 3 endpoints in ulcerative colitis trial

June 22, 2026 6:45 AM

Merck (NYSE: MRK) announced positive topline results from its Phase 3 ATLAS-UC induction-only study evaluating tulisokibart, an investigational monoclonal antibody ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found